# Alivus Life Sciences (NSE: ALIVUS) share price, financials and shareholding

Source: https://app.pivotnow.in/stock/ALIVUS · Pivot · prices to 21 Oct 2026

Alivus Life Sciences (NSE: ALIVUS) closed at ₹1,240.20 on 21 Oct 2026, down 0.46% on the day. With a market capitalisation of ₹15,367 Cr, it ranks 420th by market cap among the 4,183 NSE companies Pivot tracks (a small-cap company by SEBI's rank bands). It belongs to the Pharma & Healthcare sector; its industry is Drug Manufacturers - Specialty & Generic.

At its last close the stock traded at 27.3× trailing earnings, against a return on equity of 17.2% in FY25. Over the past year the share price has risen 35.1%. Its 52-week range is ₹819.00 (22 Jan 2026) to ₹1,493.80 (31 Aug 2026); the last close is 17.0% below the high. In Q1 FY27, the quarter ended 30 Jun 2026, revenue was ₹640 Cr (+6.4% year on year) and net profit ₹160 Cr (+31.7%), on a standalone basis. Promoters held 74.87% of the company as of 30 Jun 2026.

## Key numbers

| Metric | Value |
| --- | --- |
| Last close | ₹1,240.20 |
| Market cap | ₹15,367 Cr |
| P/E (trailing) | 27.3 |
| ROE | 17.2% (FY25) |
| ROCE | 22.3% (FY25) |
| Debt to equity | 0 |
| 52-week high | ₹1,493.80 (31 Aug 2026) |
| 52-week low | ₹819.00 (22 Jan 2026) |
| 1-year return | +35.1% |

## Quarterly results (₹ crore, standalone)

| Quarter | Revenue | Revenue YoY | Net profit | Net profit YoY | EPS (₹) |
| --- | --- | --- | --- | --- | --- |
| Q1 FY27 | ₹640 Cr | +6.4% | ₹160 Cr | +31.7% | ₹13.04 |
| Q4 FY26 | ₹689 Cr | +6.1% | ₹163 Cr | +14.7% | ₹13.23 |
| Q3 FY26 | ₹673 Cr | +4.8% | ₹150 Cr | +9.7% | ₹12.25 |
| Q2 FY26 | ₹588 Cr | +16.0% | ₹130 Cr | +36.4% | ₹10.60 |
| Q1 FY26 | ₹602 Cr | +2.2% | ₹122 Cr | +9.0% | ₹9.91 |
| Q4 FY25 | ₹650 Cr | +21.0% | ₹142 Cr | +44.9% | ₹11.57 |
| Q3 FY25 | ₹642 Cr | +12.1% | ₹137 Cr | +15.3% | ₹11.18 |
| Q2 FY25 | ₹507 Cr | −14.9% | ₹95 Cr | −19.7% | ₹7.78 |

## Annual results (₹ crore)

| Fiscal year | Revenue | Net profit |
| --- | --- | --- |
| FY25 | ₹2,387 Cr | ₹486 Cr |
| FY24 | ₹2,283 Cr | ₹471 Cr |
| FY23 | ₹2,161 Cr | ₹467 Cr |
| FY22 | ₹2,123 Cr | ₹419 Cr |
| FY21 | ₹1,885 Cr | ₹352 Cr |

## Shareholding (30 Jun 2026)

- Promoters: 74.87%
- Foreign institutions: 5.54%
- Domestic institutions: 7.18%
- Non-institutions: 12.41%

## Peers

| Company | Price | Market cap | P/E | ROE |
| --- | --- | --- | --- | --- |
| [Onesource Specialty Pharma](https://app.pivotnow.in/stock/ONESOURCE) | ₹1,371.40 | ₹15,723 Cr | — | −1.3% |
| [Syngene International](https://app.pivotnow.in/stock/SYNGENE) | ₹389.35 | ₹15,717 Cr | 49.4 | 6.5% |
| [Eris Lifesciences](https://app.pivotnow.in/stock/ERIS) | ₹1,129.50 | ₹15,652 Cr | 24.9 | 15.9% |
| [Alembic Pharmaceuticals](https://app.pivotnow.in/stock/APLLTD) | ₹785.00 | ₹15,430 Cr | 22.9 | 11.2% |
| [Poly Medicure](https://app.pivotnow.in/stock/POLYMED) | ₹1,502.40 | ₹15,228 Cr | 47.4 | 10.4% |
| [AstraZeneca Pharma India](https://app.pivotnow.in/stock/ASTRAZEN) | ₹6,055.50 | ₹15,139 Cr | 80.9 | 15.0% |

## Questions and answers

### What is the share price of Alivus Life Sciences today?

Alivus Life Sciences (NSE: ALIVUS) last closed at ₹1,240.20 on 21 Oct 2026. Its 52-week high is ₹1,493.80 and its 52-week low is ₹819.00.

### What is the market cap of Alivus Life Sciences?

Alivus Life Sciences' market capitalisation is ₹15,367 Cr (₹15,367 Cr) at the 21 Oct 2026 close, ranking 420th among the NSE companies Pivot tracks.

### What is the P/E ratio of Alivus Life Sciences?

Alivus Life Sciences trades at a trailing P/E of 27.3. The median P/E of the 5 closest Pharma & Healthcare peers by market cap is 47.4.

### What is the ROE and ROCE of Alivus Life Sciences?

Return on equity was 17.2% in FY25 and return on capital employed was 22.3% in FY25 (standalone figures).

### Is Alivus Life Sciences a debt-free company?

Alivus Life Sciences is close to debt-free: its debt-to-equity ratio was 0 in FY25.

### What were Alivus Life Sciences' latest quarterly results?

For Q1 FY27 (quarter ended 30 Jun 2026), Alivus Life Sciences reported revenue of ₹640 Cr, +6.4% year on year, and net profit of ₹160 Cr, +31.7% year on year.

### How has Alivus Life Sciences stock performed over the last year?

Alivus Life Sciences' share price has risen 35.1% over the past year, +9.4% over three months and −12.4% over one month, to the 21 Oct 2026 close.

### What is the shareholding pattern of Alivus Life Sciences?

As of 30 Jun 2026: promoters 74.87%, foreign institutions 5.54%, domestic institutions 7.18%, non-institutions 12.41%.

### Who are Alivus Life Sciences' competitors?

The listed Pharma & Healthcare companies closest to Alivus Life Sciences by market cap are Onesource Specialty Pharma, Syngene International, Eris Lifesciences, Alembic Pharmaceuticals, Poly Medicure and AstraZeneca Pharma India.

### Is Alivus Life Sciences a good stock to buy?

Pivot does not give buy or sell recommendations. This page sets out Alivus Life Sciences' price history, valuation, profitability, quarterly results and ownership so you can judge it yourself, and Pivot's chart lets you test a strategy on ALIVUS against its own history before risking money. This is analysis, not financial advice.

---

Sources: NSE end-of-day bars (Pivot's market data store); Company filings via Moneycontrol; Exchange shareholding-pattern filings. This is analysis, not financial advice. Pivot is not a broker or a SEBI-registered investment adviser.